BACKGROUND & AIMS: We developed a granulocyte-macrophage-colony-stimulating factor (GM-CSF) tumor vaccine for esophageal cancer. We evaluated the effectiveness of the vaccine as a prevention option in a surgical reflux rat model of esophageal cancer. METHODS: A surgical model involving a jejuno-esophagostomy was used to create Barrett's esophagus and esophageal cancer in rats. No carcinogen exposure was utilized. Cell lines derived from these tumors were stably passaged in vitro. GM-CSF-secreting tumor cells were generated using stable transfection. All rats underwent a total gastrectomy, followed by a jejuno-esophagostomy. The surgery promoted the reflux of duodenal contents into the esophagus. All animals were administered either a GM-CSF secreting whole cell vaccine or a phosphate-buffered saline (PBS) placebo injection 4, 6, 14, and 16 weeks post-surgery. RESULTS: While 15 of 16 animals in the non-vaccinated placebo group developed esophageal cancer, 94% (15 of 16), animals in the vaccine group had an incidence of cancer of 25% (4 of 16) (p<0.05). Barrett's esophagus was seen in 100% (16 of 16) of the controls and 83% (13 of 16) of the vaccinated animals. CONCLUSIONS: A GM-CSF-secreting whole cell tumor vaccine impeded esophageal tumor growth, but not the development of Barrett's esophagus, in a clinically relevant surgical reflux model.
BACKGROUND & AIMS: We developed a granulocyte-macrophage-colony-stimulating factor (GM-CSF) tumor vaccine for esophageal cancer. We evaluated the effectiveness of the vaccine as a prevention option in a surgical reflux rat model of esophageal cancer. METHODS: A surgical model involving a jejuno-esophagostomy was used to create Barrett's esophagus and esophageal cancer in rats. No carcinogen exposure was utilized. Cell lines derived from these tumors were stably passaged in vitro. GM-CSF-secreting tumor cells were generated using stable transfection. All rats underwent a total gastrectomy, followed by a jejuno-esophagostomy. The surgery promoted the reflux of duodenal contents into the esophagus. All animals were administered either a GM-CSF secreting whole cell vaccine or a phosphate-buffered saline (PBS) placebo injection 4, 6, 14, and 16 weeks post-surgery. RESULTS: While 15 of 16 animals in the non-vaccinated placebo group developed esophageal cancer, 94% (15 of 16), animals in the vaccine group had an incidence of cancer of 25% (4 of 16) (p<0.05). Barrett's esophagus was seen in 100% (16 of 16) of the controls and 83% (13 of 16) of the vaccinated animals. CONCLUSIONS: A GM-CSF-secreting whole cell tumor vaccine impeded esophageal tumor growth, but not the development of Barrett's esophagus, in a clinically relevant surgical reflux model.
Authors: Leisha A Emens; Deborah Armstrong; Barbara Biedrzycki; Nancy Davidson; Janice Davis-Sproul; John Fetting; Elizabeth Jaffee; Beth Onners; Steve Piantadosi; Richard T Reilly; Vered Stearns; Irena Tartakovsky; Kala Visvanathan; Antonio Wolff Journal: Hum Gene Ther Date: 2004-03 Impact factor: 5.695
Authors: J W Simons; E M Jaffee; C E Weber; H I Levitsky; W G Nelson; M A Carducci; A J Lazenby; L K Cohen; C C Finn; S M Clift; K M Hauda; L A Beck; K M Leiferman; A H Owens; S Piantadosi; G Dranoff; R C Mulligan; D M Pardoll; F F Marshall Journal: Cancer Res Date: 1997-04-15 Impact factor: 12.701
Authors: Navtej S Buttar; Kenneth K Wang; Olga Leontovich; Jay Y Westcott; Rodney J Pacifico; Marlys A Anderson; Krishnawatie K Krishnadath; Lori S Lutzke; Lawrence J Burgart Journal: Gastroenterology Date: 2002-04 Impact factor: 22.682
Authors: J W Simons; B Mikhak; J F Chang; A M DeMarzo; M A Carducci; M Lim; C E Weber; A A Baccala; M A Goemann; S M Clift; D G Ando; H I Levitsky; L K Cohen; M G Sanda; R C Mulligan; A W Partin; H B Carter; S Piantadosi; F F Marshall; W G Nelson Journal: Cancer Res Date: 1999-10-15 Impact factor: 12.701
Authors: Pramod Bonde; Guoping Sui; Surajit Dhara; Jiaai Wang; Apoorv Broor; Irene F Kim; John E Wiley; Guy Marti; Mark Duncan; Elizabeth Jaffee; Elizabeth Montgomery; Anirban Maitra; John W Harmon Journal: J Thorac Cardiovasc Surg Date: 2007-03 Impact factor: 5.209
Authors: Colman K Byrnes; Anil Bahadursingh; Nabeel Akhter; Narasimham L Parinandi; Viswanathan Natarajan; Elizabeth Montgomery; Tarik Tihan; Mark D Duncan; Petra H Nass; John W Harmon Journal: J Gastrointest Surg Date: 2003-02 Impact factor: 3.452
Authors: R Soiffer; T Lynch; M Mihm; K Jung; C Rhuda; J C Schmollinger; F S Hodi; L Liebster; P Lam; S Mentzer; S Singer; K K Tanabe; A B Cosimi; R Duda; A Sober; A Bhan; J Daley; D Neuberg; G Parry; J Rokovich; L Richards; J Drayer; A Berns; S Clift; L K Cohen; R C Mulligan; G Dranoff Journal: Proc Natl Acad Sci U S A Date: 1998-10-27 Impact factor: 11.205
Authors: Tomoharu Miyashita; Furhawn A Shah; Guy P Marti; Todd D Armstrong; Jiaai Wang; Pramod Bonde; Michael K Gibson; Kiyoshi Yoshimura; Elizabeth A Montgomery; Mark Duncan; Elizabeth M Jaffee; John W Harmon Journal: Dig Dis Sci Date: 2008-03-15 Impact factor: 3.199